356 related articles for article (PubMed ID: 26303875)
21. Validation of current procedural terminology codes for rotavirus vaccination among infants in two commercially insured US populations.
Hoffman V; Everage NJ; Quinlan SC; Skerry K; Esposito D; Praet N; Rosillon D; Holick CN; Dore DD
Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1465-1469. PubMed ID: 27623759
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK.
Martin A; Batty A; Roberts JA; Standaert B
Vaccine; 2009 Jul; 27(33):4520-8. PubMed ID: 19446594
[TBL] [Abstract][Full Text] [Related]
23. Potential impact and cost-effectiveness of rotavirus vaccination in Afghanistan.
Anwari P; Debellut F; Pecenka C; Parwiz SM; Clark A; Groman D; Safi N
Vaccine; 2018 Dec; 36(51):7769-7774. PubMed ID: 29107346
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana.
Abbott C; Tiede B; Armah G; Mahmoud A
Vaccine; 2012 Mar; 30(15):2582-7. PubMed ID: 22321664
[TBL] [Abstract][Full Text] [Related]
25. Cost effectiveness of a pentavalent rotavirus vaccine in Oman.
Al Awaidy ST; Gebremeskel BG; Al Obeidani I; Al Baqlani S; Haddadin W; O'Brien MA
BMC Infect Dis; 2014 Jun; 14():334. PubMed ID: 24941946
[TBL] [Abstract][Full Text] [Related]
26. Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A Cost-effectiveness Modeling Analysis.
Paternina-Caicedo A; De la Hoz-Restrepo F; Alvis-Guzmán N
Pediatr Infect Dis J; 2015 Jul; 34(7):e176-84. PubMed ID: 25923424
[TBL] [Abstract][Full Text] [Related]
27. Re-evaluating the cost and cost-effectiveness of rotavirus vaccination in Bangladesh, Ghana, and Malawi: A comparison of three rotavirus vaccines.
Pecenka C; Debellut F; Bar-Zeev N; Anwari P; Nonvignon J; Shamsuzzaman M; Clark A
Vaccine; 2018 Nov; 36(49):7472-7478. PubMed ID: 30420039
[TBL] [Abstract][Full Text] [Related]
28. Projected impact, cost-effectiveness, and budget implications of rotavirus vaccination in Mongolia.
Lusvan ME; Debellut F; Clark A; Demberelsuren S; Otgonbayar D; Batjargal T; Purevsuren S; Groman D; Tate J; Pecenka C
Vaccine; 2019 Feb; 37(6):798-807. PubMed ID: 30639458
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of rotavirus vaccination in Turkey.
Koksal T; Akelma AZ; Koksal AO; Kutukoglu I; Ozdemir O; Yuksel CN; Bozkaya D; Catal F; Sari S
J Microbiol Immunol Infect; 2017 Oct; 50(5):693-699. PubMed ID: 27107612
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of Rotavirus Vaccination: A Systematic Review of the First Decade of Global Postlicensure Data, 2006-2016.
Jonesteller CL; Burnett E; Yen C; Tate JE; Parashar UD
Clin Infect Dis; 2017 Sep; 65(5):840-850. PubMed ID: 28444323
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of Monovalent and Pentavalent Rotavirus Vaccines in Guatemala.
Gastañaduy PA; Contreras-Roldán I; Bernart C; López B; Benoit SR; Xuya M; Muñoz F; Desai R; Quaye O; Tam KI; Evans-Bowen DK; Parashar UD; Patel M; McCracken JP
Clin Infect Dis; 2016 May; 62 Suppl 2():S121-6. PubMed ID: 27059345
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation.
Fisman DN; Chan CH; Lowcock E; Naus M; Lee V
Vaccine; 2012 Dec; 30(52):7601-7. PubMed ID: 23107595
[TBL] [Abstract][Full Text] [Related]
33. Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, 2012-2013.
Payne DC; Selvarangan R; Azimi PH; Boom JA; Englund JA; Staat MA; Halasa NB; Weinberg GA; Szilagyi PG; Chappell J; McNeal M; Klein EJ; Sahni LC; Johnston SH; Harrison CJ; Baker CJ; Bernstein DI; Moffatt ME; Tate JE; Mijatovic-Rustempasic S; Esona MD; Wikswo ME; Curns AT; Sulemana I; Bowen MD; Gentsch JR; Parashar UD
Clin Infect Dis; 2015 Dec; 61(12):1792-9. PubMed ID: 26449565
[TBL] [Abstract][Full Text] [Related]
34. Introduction of rotavirus vaccination in Palestine: An evaluation of the costs, impact, and cost-effectiveness of ROTARIX and ROTAVAC.
Debellut F; Jaber S; Bouzya Y; Sabbah J; Barham M; Abu-Awwad F; Hjaija D; Ramlawi A; Pecenka C; Clark A; Mvundura M
PLoS One; 2020; 15(2):e0228506. PubMed ID: 32023295
[TBL] [Abstract][Full Text] [Related]
35. Public health impact of Rotarix vaccination among commercially insured children in the United States.
Krishnarajah G; Kageleiry A; Korves C; Lefebvre P; Duh MS
Vaccine; 2017 Sep; 35(37):5065-5072. PubMed ID: 28778611
[TBL] [Abstract][Full Text] [Related]
36. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
[TBL] [Abstract][Full Text] [Related]
37. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel.
Chodick G; Waisbourd-Zinman O; Shalev V; Kokia E; Rabinovich M; Ashkenazi S
Eur J Public Health; 2009 Jun; 19(3):254-9. PubMed ID: 19221026
[TBL] [Abstract][Full Text] [Related]
38. Economic evaluation of rotavirus vaccination: an important step of the introduction to the national immunization program in Thailand.
Rochanathimoke O; Riewpaiboon A; Praditsitthikorn N; Tharmaphornpilas P; Jiamsiri S; Thavorncharoensap M; Postma MJ
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):811-819. PubMed ID: 34008471
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of a pentavalent rotavirus vaccine in Japan.
Itzler R; O'Brien MA; Yamabe K; Abe M; Dhankhar P
J Med Econ; 2013 Oct; 16(10):1216-27. PubMed ID: 23919721
[TBL] [Abstract][Full Text] [Related]
40. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand.
Muangchana C; Riewpaiboon A; Jiamsiri S; Thamapornpilas P; Warinsatian P
Vaccine; 2012 Apr; 30(18):2839-47. PubMed ID: 22387220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
